Institut Paoli Calmettes Breast Cancer Database
1 other identifier
observational
45,000
1 country
1
Brief Summary
Database of Institut Paoli-Calmettes patients diagnosed with breast cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 1995
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 1995
CompletedFirst Submitted
Initial submission to the registry
August 3, 2016
CompletedFirst Posted
Study publicly available on registry
August 17, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2030
August 17, 2016
August 1, 2016
35 years
August 3, 2016
August 16, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Survival of patients with breast cancer
Overall survival of all patients who come in the center
10 years
Secondary Outcomes (1)
Collection of patients characteristics
10 years
Study Arms (1)
Patients with breast cancer diagnosis
Interventions
Eligibility Criteria
Patients with a diagnosis of Breat Cancer
You may qualify if:
- Patient with a diagnosis of breast cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institut Paoli Calmettes
Marseille, Bouches du Rhone, 13009, France
Related Publications (2)
Houvenaeghel G, de Nonneville A, Cohen M, Sabiani L, Buttarelli M, Charaffe E, Jalaguier A, Bannier M, Tallet A, Viret F, Goncalves A. Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival. Cancer Med. 2024 Feb;13(3):e6930. doi: 10.1002/cam4.6930. Epub 2024 Feb 7.
PMID: 38327130DERIVEDHouvenaeghel G, de Nonneville A, Cohen M, Chopin N, Coutant C, Reyal F, Mazouni C, Gimbergues P, Azuar AS, Chauvet MP, Classe JM, Darai E, Martinez A, Rouzier R, de Lara CT, Lambaudie E, Barrou J, Goncalves A. Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆. ESMO Open. 2021 Jun;6(3):100151. doi: 10.1016/j.esmoop.2021.100151. Epub 2021 May 10.
PMID: 33984674DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 3, 2016
First Posted
August 17, 2016
Study Start
January 1, 1995
Primary Completion (Estimated)
January 1, 2030
Study Completion (Estimated)
December 1, 2030
Last Updated
August 17, 2016
Record last verified: 2016-08
Data Sharing
- IPD Sharing
- Will not share